<DOC>
	<DOCNO>NCT02973087</DOCNO>
	<brief_summary>The purpose phase 3 study investigate efficacy safety , include immunogenicity thrombogenicity prophylactic treatment recombinant von Willebrand factor ( rVWF ) subject severe von Willebrand disease ( VWD ) .</brief_summary>
	<brief_title>rVWF IN PROPHYLAXIS</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Participant document diagnosis severe von Willebrand disease ( VWD ) ( baseline Von Willebrand factor : Ristocetin cofactor activity ( VWF : RCo ) &lt; 20 IU/dL ) history require substitution therapy von Willebrand factor concentrate control bleed 1 . Type 1 ( VWF : RCo &lt; 20 IU/dL ) , 2 . Type 2A ( verified multimer pattern ) , Type 2B ( diagnose genotype ) , Type 2M , 3 . Type 3 ( VWF : Ag ≤3 IU/dL ) . 2 . Diagnosis confirm genetic test multimer analysis , document patient history screening . 3 . Participant currently receive ondemand treatment prophylactic treatment recommend accord standard care center . 4 . Has ≥3 document spontaneous bleeds require von Willebrand factor ( VWF ) treatment past 12 month 5 . Availability record reliably evaluate type , frequency treatment bleed episode 12 month ondemand treatment prior enrollment . 6 . Participant ≥18 year old time screen body mass index ≥15 &lt; 40 kg/m^2 . 7 . If female childbearing potential , participant present negative blood/urine pregnancy test screen agrees employ adequate birth control measure duration study . 8 . Participant willing able comply requirement protocol . 1 . Participant diagnosed Type 2N von Willebrand disease ( VWD ) , pseudo VWD , another hereditary acquire coagulation disorder VWD ( eg qualitative quantitative platelet disorder elevate prothrombin time ( PT ) / international normalize ratio ( INR ) &gt; 1.4 ) . 2 . Participant receive prophylaxis treatment 12 month prior screen ( include receive treatment month menorrhagia treat bleeds ) . 3 . Participant currently receive prophylaxis treatment . 4 . Participant history presence VWF inhibitor screen . 5 . Participant history presence Factor VIII ( FVIII ) inhibitor titer ≥0.4 BU ( Nijmegen modify Bethesda assay ) ≥0.6 Bethesda Unit ( BU ) ( Bethesda assay ) . 6 . Participant know hypersensitivity component study drug , mouse hamster protein . 7 . Participant medical history immunological disorder , exclude seasonal allergic rhinitis/conjunctivitis , mild asthma , food allergy animal allergy . 8 . Participant medical history thromboembolic event . 9 . Participant human immunodeficiency virus ( HIV ) positive absolute Helper T cell ( CD4 ) count &lt; 200/mm^3 . 10 . Participant diagnose significant liver disease evidence follow : serum Alanine aminotransferase ( ALT ) 5 time Upper limit normal ( ULN ) ; hypoalbuminemia ; portal vein hypertension ( e.g. , presence otherwise unexplained splenomegaly , history esophageal varix ) . 11 . Participant diagnose renal disease , serum creatinine level ≥2.5 mg/dL . 12 . Participant platelet count &lt; 100,000/mL screening . 13 . Participant treat immunomodulatory drug , exclude topical treatment ( e.g. , ointment , nasal spray ) , within 30 day prior sign inform consent . 14 . Participant pregnant lactating time enrollment . 15 . Participant cervical uterine condition cause menorrhagia metrorrhagia ( include infection , dysplasia ) . 16 . Participant participate another clinical study involve another Investigational product ( IP ) investigational device within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study . 17 . Participant progressive fatal disease and/or life expectancy le 15 month . 18 . Participant identify investigator unable unwilling cooperate study procedure . 19 . The subject mental condition render him/her unable understand nature , scope possible consequence study and/or evidence uncooperative attitude . 20 . Participant prison compulsory detention regulatory and/or juridical order . 21 . Participant member study team dependent relationship one study team member include close relative ( i.e. , child , partner/spouse , sibling parent ) well employee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>